Prodigiosin inhibits proliferation and metastasis in head and neck squamous cell carcinoma: insights from phenotypic validation and network pharmacology.

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) exhibits significant heterogeneity and poor survival rates in advanced stages, necessitating novel therapeutic strategies. Prodigiosin, a natural bacterial metabolite with demonstrated anticancer properties in other malignancies, has not been thoroughly investigated in HNSCC. This study aimed to investigate the antitumor effects of prodigiosin and elucidate its underlying mechanisms in HNSCC.

METHODS: An integrated approach combining network pharmacology prediction with experimental validation was employed. In vitro assays (CCK-8, EdU, colony formation, tumorsphere, transwell migration and invasion) assessed prodigiosin's effects on carcinogenesis across HNSCC cell lines. A subcutaneous xenograft mouse model evaluated antitumor efficacy and lymph node metastasis in vivo. Potential targets and pathways identified by network pharmacology were subsequently validated through molecular docking followed by 100-ns molecular dynamics simulations. Functional experiments were performed to the effect of prodigiosin on HNSCC targets and pathway.

RESULTS: Prodigiosin potently inhibited HNSCC proliferation in vitro and significantly suppressed tumor growth in vivo. In addition, it attenuated cancer stemness, migration, and invasion, and significantly reduced the lymph node metastatic burden in mice. Network analysis identified 159 shared targets, with EGFR, BCL2, ERBB2, PPARG, and PTGS2 identified as core hubs. Enrichment analysis highlighted pathways including PI3K-AKT signaling and apoptosis. Molecular docking confirmed high-affinity binding of prodigiosin to all five core targets, and MD simulations demonstrated stable complex formation over 100 ns. Functional experiment solidifies that EGFR and PI3K-AKT pathway was inhibited by prodigiosin and BCL2 was the key target.

CONCLUSION: This study demonstrates that prodigiosin exerts potent multi-target antitumor effects against HNSCC by inhibiting proliferation, metastasis, and cancer stemness, both in vitro and in vivo. Its efficacy is mechanistically associated with high-affinity binding and modulation of key targets and critical pathways. Collectively, these findings suggest Prodigiosin is a promising novel multi-target therapeutic candidate for HNSCC treatment.